Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis.
Nihar R DesaiCaresse CampbellBatul ElectricwalaMargaret PetrouDavid TruemanFionn WoodcockJoaquim CristinoPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2022)
This study identified the price at which inclisiran is cost effective for the US health system, at generally accepted willingness-to-pay thresholds.
Keyphrases